Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Topical Antibiotics and Intravitreous Injections

This study has been completed.
Information provided by (Responsible Party):
Christopher Ta, Stanford University Identifier:
First received: October 2, 2006
Last updated: May 13, 2014
Last verified: May 2014
Results First Received: May 13, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Single Group Assignment;   Masking: Single Blind (Investigator)
Conditions: Intravitreous
Intervention: Drug: gatifloxacin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Topical Antibiotic

topical gatifloxacin 4 times per day


Participant Flow:   Overall Study
    Topical Antibiotic
STARTED   129 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
patient undergoing IVT

Reporting Groups
Topical Antibiotic

topical gatifloxacin 4 times per day


Baseline Measures
   Topical Antibiotic 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 77  (13) 
[Units: Participants]
Female   81 
Male   48 

  Outcome Measures

1.  Primary:   Positive Culture   [ Time Frame: 2 ]

2.  Primary:   Conjunctival Bacterial Flora   [ Time Frame: 3 days ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Professor
Organization: Stanford
phone: 6504984791

Responsible Party: Christopher Ta, Stanford University Identifier: NCT00410891     History of Changes
Other Study ID Numbers: 96803 (eProtocol 4384
Study First Received: October 2, 2006
Results First Received: May 13, 2014
Last Updated: May 13, 2014